Patent Evaluation: Effective, non-cytopathic TAT protein inhibitors for the treatment of HIV infections: Current Opinion on Therapeutic Patents: Vol 2, No 3

Views

CrossRef citations to date

Altmetric

Summary

Novelty: Antiretroviral 2-amino-1,4-benzodiazepines are claimed for the treatment of HIV infections.

Biology: The in vitro activity of two compounds is disclosed. ID50 values for reducing the number of HIV infected cells are in the range of 0.5–1 μM. Data from anti-TAT assays are also detailed.

Structure:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Patent Evaluation: Effective, non-cytopathic TAT protein inhibitors for the treatment of HIV infections

Information for

Open access

Opportunities

Help and information

Patent Evaluation: Effective, non-cytopathic TAT protein inhibitors for the treatment of HIV infections

Summary

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature